image loading
(from DailyMed)

M-Natal Plus Vitamin A, Vitamin C, Vitamin D, Vitamin E, Thiamine, Riboflavin, Niacin, Vitamin B6, Folic Acid, Vitamin B12, Calcium, Iron, Zinc, Copper 4000 [iU]/1; 120 mg; 400 [iU]/1; 22 [iU]/1; 1.84 mg; 3 mg; 20 mg; 10 mg; 1 mg; 12 ug; 200 mg Tablet, 100-count

by METHOD PHARMACEUTICALS, LLC · 100 TABLET in 1 BOTTLE (58657-170-01)
NDC 58657-0170-01
🏷️ FDA NDC (as labeled) 58657-170-01 billing pads the product segment with a zero
Rx only On market Non-controlled
🗂️ Data synced Sep 17, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 58657-170-01
Product NDC 58657-170
11-digit billing NDC 58657017001
NCPDP billing unit EA — each (per item)
UNII 81G40H8B0T, PQ6CK8PD0R, 9VU1KI44GP, 9E8X80D2L0, X66NSO3N35, TLM2976OFR +8 more
SPL Set ID 1f8785db-3e65-49d7-b017-b1a65b5ec6b1
Established class (EPC) Vitamin A; Vitamin C; Nicotinic Acid; Vitamin B12; Calcium; Copper-containing Intrauterine Device
Physiologic effect Decreased Embryonic Implantation; Decreased Sperm Motility; Inhibit Ovum Fertilization
Chemical class Vitamin A; Ascorbic Acid; Nicotinic Acids; Vitamin B 12; Calcium; Copper
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-10-01
Route ORAL
Dosage form TABLET
Substance VITAMIN A; ASCORBIC ACID; VITAMIN D; .ALPHA.-TOCOPHEROL ACETATE; THIAMINE; RIBOFLAVIN; NIACIN; PYRIDOXINE HYDROCHLORIDE; FOLIC ACID; CYANOCOBALAMIN; CALCIUM; FERROUS FUMARATE; ZINC; COPPER
GPI-14 78512015000324
GPI class M-Natal Plus
GCN Seq No 066420
GCN 28688
HICL code 037025
Ingredient (HICL) Pnv,Calcium 72/Iron/Folic Acid
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C6
Therapeutic class — intermediate (HIC2) Vitamins
HIC3 code C6F
Therapeutic class — specific (HIC3) Prenatal Vitamin Preparations
AHFS code 20:04.04.00
AHFS class Iron Preparations
FDB label name M-NATAL PLUS TABLET
FDB brand name M-Natal Plus
Legend status Q — Non-drug — dietary supplement, vitamin, medical food, or herbal preparation
Why two NDCs? The FDA registers this code as 58657-170-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 58657-0170-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerMETHOD PHARMACEUTICALS, LLC
Labeler code58657
First marketedOct 2018
Product typeHuman Prescription Drug
Portfolio78 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name M-NATAL PLUS TABLET Ingredient Pnv,Calcium 72/Iron/Folic Acid
🧪 What is this product?

M-Natal Plus is an oral tablet containing a combination of vitamins and minerals. The product includes vitamins A, C, D, and E along with B vitamins (thiamine, riboflavin, niacin, vitamin B6, folic acid, and vitamin B12), which are typically used to support nutrition and metabolism. It also contains minerals including calcium, iron, zinc, and copper, which are commonly used to support bone health, oxygen transport, and immune function. This product is marketed without an approved FDA application.

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII T9D99G2B1R
    Caramel is a brown coloring substance made by heating sugar. It's added to medicines to give them color and sometimes a slight sweet taste without affecting how the drug works.
  • UNII R12CBM0EIZ
    A natural wax derived from a Brazilian palm tree, used as a coating and polish on tablets and capsules. It creates a smooth, shiny finish that protects the medicine and improves appearance.
  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 3WJQ0SDW1A
    Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
  • UNII 532B59J990
    Polyvinyl alcohol is a synthetic polymer made from plant-derived materials. It's used as a binder to hold ingredients together, a film-former in coatings, and a thickener in liquid formulations.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
  • UNII 7SEV7J4R1U
    A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

11 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.105 $10.54 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2553 $25.53 / 100 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.127 $0.101
▼ Down 9% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
M-Natal Plus 4000 [iU]/1; 120 mg/1; 400 [iU]/1; 22 [iU]/1; 1.84 mg/1; 3 mg/1; 20 mg/1; 10 mg/1; 1 mg/1; 12 ug/1; 200 mgthis 58657-0170-01 METHOD 100 tablets $0.105 Availability likely
M-Natal Plus 4000 [iU]/1; 120 mg/1; 400 [iU]/1; 22 [iU]/1; 1.84 mg/1; 3 mg/1; 20 mg/1; 10 mg/1; 1 mg/1; 12 ug/1; 200 mg 63629-1140-01 Bryant 100 tablets FDA listed
M-Natal Plus 4000 [iU]/1; 120 mg/1; 400 [iU]/1; 22 [iU]/1; 1.84 mg/1; 3 mg/1; 20 mg/1; 10 mg/1; 1 mg/1; 12 ug/1; 200 mg 72162-1658-01 Bryant 100 tablets FDA listed
M-Natal Plus 4000 [iU]/1; 120 mg/1; 400 [iU]/1; 22 [iU]/1; 1.84 mg/1; 3 mg/1; 20 mg/1; 10 mg/1; 1 mg/1; 12 ug/1; 200 mg 70518-3579-00 REMEDYREPACK 30 tablets Discontinued
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Oct 2018
📍
2026
Currently FDA-listed
8 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 58657-0170-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
135.4K
Units reimbursed last 4 qtrs
5.7M
Gross reimbursed last 4 qtrs
$1.46M
Avg / prescription
$10.75
Avg / unit
$0.2553
Latest quarter Q1 2026
29.8KRx
Medicaid pays / ea
$0.2553
gross reimbursed
vs
NADAC / ea
$0.1054
acquisition cost
=
Spread
+$0.1499
+142% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
27% FFS 73% MCO
Fee-for-service · 36,592 Rx Managed care · 98,822 Rx
State Medicaid map
Alaska: 28,428 units · 3,878 per 100k residents AK Maine: 26,956 units · 1,932 per 100k residents ME Washington: 153,842 units · 1,969 per 100k residents WA Idaho: 7,446 units · 379 per 100k residents ID Montana: 19,607 units · 1,732 per 100k residents MT North Dakota: 16,766 units · 2,141 per 100k residents ND Minnesota: 103,597 units · 1,806 per 100k residents MN Wisconsin: 151,063 units · 2,556 per 100k residents WI Michigan: 713,629 units · 7,110 per 100k residents MI New York: 600,151 units · 3,067 per 100k residents NY Vermont: 22,694 units · 3,508 per 100k residents VT New Hampshire: 3,123 units · 223 per 100k residents NH Oregon: 50,528 units · 1,194 per 100k residents OR Nevada: 7,560 units · 237 per 100k residents NV Wyoming: no data reported WY South Dakota: 17,803 units · 1,937 per 100k residents SD Iowa: 28,506 units · 889 per 100k residents IA Illinois: 177,680 units · 1,416 per 100k residents IL Indiana: 122,781 units · 1,789 per 100k residents IN Ohio: 498,930 units · 4,234 per 100k residents OH Pennsylvania: 766,516 units · 5,914 per 100k residents PA New Jersey: 80,834 units · 870 per 100k residents NJ Massachusetts: 306,138 units · 4,373 per 100k residents MA California: 4,364 units · 11.2 per 100k residents CA Utah: 4,346 units · 127 per 100k residents UT Colorado: 34,536 units · 588 per 100k residents CO Nebraska: 53,317 units · 2,696 per 100k residents NE Missouri: 426,387 units · 6,882 per 100k residents MO Kentucky: 73,416 units · 1,622 per 100k residents KY West Virginia: 17,341 units · 980 per 100k residents WV Virginia: 5,822 units · 66.8 per 100k residents VA Maryland: 43,877 units · 710 per 100k residents MD Connecticut: 37,828 units · 1,046 per 100k residents CT Rhode Island: 930 units · 84.9 per 100k residents RI Arizona: 76,585 units · 1,031 per 100k residents AZ New Mexico: 38,372 units · 1,815 per 100k residents NM Kansas: 4,380 units · 149 per 100k residents KS Arkansas: 19,663 units · 641 per 100k residents AR Tennessee: 10,200 units · 143 per 100k residents TN North Carolina: 183,956 units · 1,698 per 100k residents NC South Carolina: 15,360 units · 286 per 100k residents SC Delaware: 6,552 units · 635 per 100k residents DE Oklahoma: 43,044 units · 1,062 per 100k residents OK Louisiana: 125,171 units · 2,737 per 100k residents LA Mississippi: 59,023 units · 2,008 per 100k residents MS Alabama: 27,945 units · 547 per 100k residents AL Georgia: 48,655 units · 441 per 100k residents GA D.C.: 1,899 units · 280 per 100k residents DC Hawaii: 710 units · 49.5 per 100k residents HI Texas: 92,104 units · 302 per 100k residents TX Florida: 209,284 units · 926 per 100k residents FL
Units reimbursed · per 100k residents
11.27,110
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Michigan 7,110 /100k
2 Missouri 6,882 /100k
3 Pennsylvania 5,914 /100k
4 Massachusetts 4,373 /100k
5 Ohio 4,234 /100k
6 Alaska 3,878 /100k
7 Vermont 3,508 /100k
8 New York 3,067 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for M-Natal Plus — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name M-Natal Plus. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$36.9K
Claims incl. refills
4.7K
Beneficiaries
2.6K
Spend / beneficiary
$13.95
Spend / claim
$7.83
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
58657-0170-01 You're viewing this 100 TABLET in 1 BOTTLE (58657-170-01) 2018-10-01 Active

🧭 About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 58657-170-01, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 58657-0170-01, written without dashes as 58657017001. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 58657-0170-01, the first segment (58657) is the labeler code FDA assigned to METHOD PHARMACEUTICALS, LLC; the middle segment (0170) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by METHOD PHARMACEUTICALS, LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
METHOD PHARMACEUTICALS, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
⏱️ Dosage and Administration 26 words

DOSAGE AND ADMINISTRATION Before, during and/or after pregnancy, one tablet daily, with a meal, or as directed by a licensed healthcare practitioner regardless of lactation status.

⚠️ Warnings 38 words

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

📦 How Supplied / Storage and Handling 25 words

HOW SUPPLIED Supplied as beige tablet, imprinted "M170" dispensed in bottles of 100 tablets. Manufactured By: Method Pharmaceuticals, LLC Fort Worth, Texas 76118 Rev. 08/2018

📋 Description 26 words

DESCRIPTION M-Natal Plus Tablet is an orally administered prenatal/postnatal prescription folic acid-containing dietary supplement and should be administered under the supervision of a licensed medical practitioner.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.